NCT02052596 - Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older | Biotech Hunter

Enrollment

935

Participants

Timeline

Start Date

February 7, 2014

Primary Completion Date

June 16, 2015

Study Completion Date

April 21, 2016

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster vaccine GSK 1437173A

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

BIOLOGICAL

Boostrix

1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.

Trial Locations (13)

15401

GSK Investigational Site, Uniontown

23294

GSK Investigational Site, Richmond

28114

GSK Investigational Site, Salisbury

28209

GSK Investigational Site, Charlotte

29650

GSK Investigational Site, Greer

30281

GSK Investigational Site, Stockbridge

83642

GSK Investigational Site, Meridian

85704

GSK Investigational Site, Tucson

85712

GSK Investigational Site, Tucson

89104

GSK Investigational Site, Las Vegas

92108

GSK Investigational Site, San Diego

04240

GSK Investigational Site, Lewiston

02886

GSK Investigational Site, Warwick